GBA1 and depressive symptom measurement: The GBA1 metabolic pathway is an attractive target for neuroprotective therapy in PD.8, 9 Disease‐modifying treatments are likely to be most effective when given early, for instance during a prodromal phase of microsmia, constipation, depression, dysautonomia, rapid eye movement sleep behavior disorder (RBD), and cognitive impairment.